Answers are grounded in this paper and cite their sources.
FGFR aberrations are common in a wide variety of cancers, with the majority being gene amplifications or activating mutations. These data suggest that FGFR inhibition could be an important therapeutic option across multiple tumor types.
No takes yet. Share an insight, caveat, or question.
Helsten et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: